

\*\*\*Published July 2020\*\*\*

## MarketVIEW: Rift Valley Fever vaccines (CAT: VAMV085)

<b>Product Name</b>	:	<b>MarketVIEW:</b> Rift valley fever vaccines
<b>Description</b>	:	Global vaccine commercial opportunity assessment, global market forecast
<b>Contents</b>	:	Executive presentation (>120 slides.pdf) + 1 x MS-Excel forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	<b>Rift Valley Fever vaccines</b>
<b>Publication date</b>	:	July 2020
<b>Catalogue No</b>	:	VAMV085

## Background

**Rift Valley Fever (RVF)** is an acute zoonotic disease affecting domestic and wild ruminants and can cause moderate-to-severe illness in humans. It is caused by Rift Valley Fever Virus (RVFV), a negative single-stranded RNA arbovirus of the family *Bunyaviridae* (genus *Phlebovirus*). The main route of infection in humans is via contact with tissues and bodily fluids or consumption of raw milk from infected livestock. Mosquitos can also transmit the virus to both animals and humans. To date no human-to-human transmission has been documented.

**Rift Valley Fever** has mainly affected Sub-Saharan Africa with major outbreaks in Kenya (1997-98), Somalia and Tanzania. More recent outbreaks have occurred in Saudi Arabia and Yemen (2000-2001). It is estimated that between 1997-2010 more than 500,000 cases of RVF occurred with over 2,000 deaths reported. A main concern is that more RVF outbreaks could occur due to the existence of competent vectors in non-endemic areas. RVF can also cause significant economic damage and famine to areas reliant on livestock rearing and food trading.

**Rift Valley Fever Virus** has been designated a priority pathogen by the **Coalition of Epidemic Preparedness Innovations (CEPI)** and the **World Health Organisation**. An inactivated vaccine has been developed for human use (Special Immunization Program) but it's profile is not suitable (or licensed) for large scale deployment.

This **MarketVIEW** product is a comprehensive commercial evaluation containing an Executive Presentation (>120 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a Rift Valley Fever vaccine to 2040. The model (34 countries)\* covers 'at risk' populations or identified target segments in both the public and private sector (based on latest disease understanding). A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided along with a discussion of hypothetical vaccine target product profiles (TPPs). \*Some are rolled up

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining Rift Valley Fever in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference and FDA meeting proceedings etc. Previously published research by **VacZine Analytics** in the fields of other related emergency pathogens and their planning.

### PRODUCT CONTENTS:

Published July 2020 (CAT No: VAMV085)

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), [1 x forecast models \(.xls\)](#)

#### Contents – Summary presentation (.pdf)<sup>1</sup>

Contents  
Author's notes  
Executive summary  
**[SECTION 1]** Rift Valley Fever vaccines: key model outputs  
**[SECTION 2]** Rift Valley Fever: disease background and epidemiology  
**[SECTION 3]** Rift Valley Fever vaccines: R&D pipeline and competitor activity  
**[SECTION 4]** Rift Valley Fever vaccines: modelling commercial potential  
References/bibliography  
About **VacZine Analytics**  
Disclaimer

**SNAPSHOT**

**PAGES: >120 slides fully referenced/sourced. Available in .pdf form**

#### Contents – 1 x vaccine demand models (MS Excel-based)

**Worksheets = >100 interconnected**

<sup>1</sup> Full contents i.e. title per slide is proprietary and only visible on license purchase



**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$6,995**/ GBP **£5,595**<sup>#</sup> (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

<sup>#</sup> - *indicative prevailing rate will be applied on date of transaction*

On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations)

**HOW TO ORDER:**

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and the “spiral logo” are UK Registered Trademarks, 2009

## **BIBLIOGRAPHY**

References – proprietary



**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

A division of Assay Advantage Ltd

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 927049 / +44 (0) 7952470582

E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and “the spiral logo” are UK Registered Trademarks, 2009

